Tagged with Biosimilar

Turkey Polifarma is a Turkish pharma company dedicated to the hospital sector and biosimilars. Its chairman, Ufuk Kumrulu, explains how the company has managed to become a top two company in the hospital segment after Roche, discusses their big bet on biosimilar products through an R&D center and manufacturing plant, and…

Saudi Arabia Trad Alkhelaiwi, country director for Amgen in Saudi Arabia, discusses the intricacies of the Saudi healthcare transformation including the push for a value-based healthcare system that adopts best practices from other healthcare systems, Amgen’s upcoming launch in lung cancer, its plan to invest over USD 80 million in Saudi in…

Turkey Süha Taşpolatoğlu, CEO of Abdi Ibrahim, Turkish pharma’s “national champion”, discusses the company’s ambitious bet on biosimilars, their position as the licensing and CMO partner of choice for multinational companies interested in Turkey, and the objective of reaching one billion dollars in revenue. In addition, he outlines Abdi’s international ambitions…

Turkey Ilko Pharmaceuticals is a family-owned Turkish generics and biosimilars company. General Manager Hatice Öncel explains the company’s investment in biosimilars in collaboration with South Korea’s Genexine and how recent success in consumer health has allowed them to overperform the local market with 27 percent growth in 2020. In addition, she…

Turkey The secretary general for Turkey’s Pharmaceutical Manufacturers Association (IEIS), Savaş Malkoç, highlights their objective of increasing R&D expenditure and Turkey’s big opportunity ahead in biosimilars production. In addition, Malkoç discusses the persisting issues within the country’s pricing and reimbursement system and why localization policies have been a net gain for…

USA Dan Leonard of the Association for Accessible Medicines (AAM) highlights five key takeaways from the organisation’s remote but dynamic annual conference, and how the US generics and biosimilars industry might evolve post-COVID.   AAM and our member companies have experienced a year like no other, and the lessons of the…

Turkey As one of the leading pharma companies in Turkey, DEVA is pioneering a new approach to generics in the country. Chairman of the Board and CEO Philipp Haas discusses the company’s presence and strategy in international markets, how the firm is leveraging its three US FDA-approved and EU GMP-certified production…

Switzerland Laurent Massuyeau introduces Swiss biosimilar commercialisation specialist iQone healthcare, why it made sense to base the company in Switzerland, its partnership deal with Korean biosimilar giant Celltrion, and where iQone’s future lies.   For me, Switzerland is one of the best places in Europe to start a business Having previously…

USA Dan Leonard, president and CEO of the Association for Accessible Medicines (AAM) since August 2020, outlines his key agenda priorities as head of the USA’s largest generic industry body, how the COVID-19 pandemic has altered the discussion around generics and essential medicines, and his hopes for the Biden administration  …

China One of the largest domestic pharma companies in China (ranking number one from 2014 to 2019), Yangtze River Pharmaceutical Group (YRPG) is so-named for its location in Taizhou, Jiangsu Province, part of the Yangtze River Delta, where the Yangtze River feeds into the East China Sea. Founded initially in 1971,…

USA The AAM’s Dan Leonard highlights the savings impact that generic and biosimilar medicines have on US healthcare today and introduces the ‘Secure Our Meds’ campaign which aims to educate policymakers on the importance of generic and biosimilar market competition and how it can be safeguarded.   More than 35 years…

Switzerland Alvotech – the biosimilars arm of Icelandic-headquartered generics player Alvogen – is positioning itself for future growth via a very different strategy to that of the Big Pharma players with biosimilar portfolios. Chief Commercial Officer Anil Okay, who sits in Switzerland, explains the four company traits that he believes will…